Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 5Phase 4 2Phase 1/2 2

Status

Not yet recruiting 2Completed 2Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Limited Stage Small Cell Lung Cancer 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Interventional × trilaciclib × Clear all
NCT07473128 2026-03-16

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Pharmacosmos A/S

Phase 3 Not yet recruiting
120 enrolled
Thoracic

Limited Stage Small Cell Lung Cancer

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Not yet recruiting
210 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04607668 2024-11-26

PRESERVE1

G1 Therapeutics, Inc.

Phase 3 Terminated
326 enrolled 15 charts
Gastrointestinal

Colorectal Neoplasms

NCT04799249 2024-08-01

PRESERVE 2

G1 Therapeutics, Inc.

Phase 3 Completed
194 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04902885 2024-07-10

Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3 Completed
95 enrolled 27 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡